Buy & Sell Amgen, Inc. (AMGN) – Amgen, Inc. Price Today
Aura AI Summary
Key Stats
- $182.21BMarket Cap
- HealthSector
- -16.57%3M Drawdown
- $227.49BEnterprise Value
- 2.99%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 74 daysTypical Hold Time
Amgen, Inc. (AMGN) is currently valued at a market capitalization of $182.21B, with an enterprise value of $227.49B. Over the past 52 weeks, Amgen, Inc. has traded between a low of $271.18 and a high of $388.16, highlighting its annual price range. Over the past three months, Amgen, Inc. has recorded a drawdown of -16.57%, reflecting recent price volatility. Amgen, Inc. offers a dividend yield of 2.99%, with the most recent dividend of $2.52 paid on 15 May 26. On average, investors hold Amgen, Inc. for approximately 74 days, indicating typical investor behavior on the platform.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Most Recent News
Patient Square buys 210,000 shares of Nektar Pharmaceuticals, signaling strong confidence.
Patient Square has purchased 210,000 shares of Nektar Pharmaceuticals (NKTR), indicating a significant investment move. This purchase reflects Patient Square's confidence in Nektar's future prospects and potential growth. Investors may view this as a...
Managed futures ETF DBMF outperforms traditional 60/40 portfolios, offering strong diversification and steady returns.
The iMGP DBi Managed Futures Strategy ETF (DBMF) has gained about $3 billion in assets by delivering returns that do not closely track stocks or bonds, outperforming the traditional 60/40 equity-bond mix in 2022 and again in 2026. DBMF uses a trend-f...
Sprott Rare Earths Ex-China ETF offers unique exposure to non-Chinese rare earth companies amid rising global demand.
The Sprott Rare Earths Ex-China ETF (REXC) provides focused investment in rare earth companies outside China, including top holdings like MP Materials and Lynas Rare Earths. This ETF addresses the urgent global need for rare earth elements (REEs) sou...